BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: Acute Myeloid Leukemia (AML) Disease Coverage

April 11, 2018

Acute myeloid leukemia (AML) is a hematological malignancy characterized by the proliferation of myeloid blast cells in blood and bone marrow. There has been little change to standard treatment for AML, which is typically based on cytarabine chemotherapy with an anthracycline. Although patients aged <60 years may achieve remission with induction therapy, most patients will relapse, and the prognosis worsens with age.

This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, Pricing & Reimbursement, and Pipeline modules.

Disease Group Covered: Oncology
Back to the top Back to the top